By BowTiedBiotech on Substack · 3K+ subscribers · 11 free and 1 paid among the latest 12.
Daily Biotech Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends
Capricor Therapeutics ($CAPR) is a catalyst-driven setup centered on the expected November 22, 2026 FDA decision for deramiocel in Duchenne muscular dystrophy. The date should be treated cautiously because secondary reporting…
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week we dive into one of the most…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on additional 2026 clinical efficacy and biomarker data from the ongoing Phase 1b study of paxalisib combinations in advanced breast cancer. This is not primarily a…
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week we dive into the next…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to…
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but…
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive…